Ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
Janssen
['cilta-cel', 'cartitude-4', 'cartitude']
cartitude-4 met primary endpoint with cilta-cel improving pfs in len refractory mm with 1-3 prior lot (hr 0.26). pfs may be best in patients with 1 prior lot but data is immature and further follow up is needed. cilta-cel may also be more tolerable in early lines #asco23 
DAVA Oncology is a strategic consulting company that offers numerous products and services customized to fit biopharmaceutical drug development needs.